Engineered Virus and Immunotherapy: New Hope for Glioblastoma Brain Cancer Patients

A new study details the safe and promising use of an engineered oncolytic virus (DNX-2401) alongside immunotherapy in treating recurrent glioblastoma (GBM). Despite not meeting its primary efficacy endpoint, the study achieved a significant 12-month survival rate, exceeding the prespecified efficacy threshold.